Trials / Completed
CompletedNCT00378560
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
V501 Phase II Efficacy Study in Women Aged 18 to 26
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,021 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 18 Years – 26 Years
- Healthy volunteers
- Accepted
Summary
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | V501; Gardasil, 0.5 ml injection in 3 dosing regimen |
| BIOLOGICAL | Comparator: Placebo | Placebo 0.5 ml injection in 3 dosing regimen |
Timeline
- Start date
- 2006-06-12
- Primary completion
- 2009-09-16
- Completion
- 2009-09-16
- First posted
- 2006-09-20
- Last updated
- 2017-04-17
- Results posted
- 2010-06-29
Source: ClinicalTrials.gov record NCT00378560. Inclusion in this directory is not an endorsement.